{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:52Z","timestamp":1785168292536,"version":"3.55.0"},"reference-count":22,"publisher":"Universa BV","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Background and study aim: There are several studies comparing patients treated with lamivudine and those not given antiviral therapy in acute hepatitis B. Some of these studies showed that antiviral treatment significantly contributed to survival, whereas one other study suggested that antiviral treatment had no effect. The aim of this study was to investigate the efficacy of tenofovir disoproxil fumarate (TDF) therapy and its effect on HBsAg seroconversion in patients with acute viral hepatitis B.\n\nPatients and methods: The files of 126 patients who were under follow-up for acute HBV infection in the Department of Gastroenterology were analyzed retrospectively. Demographic data, molecular, ELISA, and biochemistry tests at the time of diagnosis and in the follow-up, period were evaluated using the hospital automation system.\n\nResults: The rate of chronicity of HBV was found to be higher in the TDF group than in the group without antiviral treatment. The rate of protective anti-HBs acquisition was found to be lower in the TDF group (p&lt;0.05).\n\nConclusion: Antiviral treatment with TDF in acute HBV infection may increase the rate of chronicity. It may reduce the development of natural immunity. Further studies are warranted.<\/jats:p>","DOI":"10.51821\/87.3.12462","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:10:44Z","timestamp":1730301044000},"page":"367-371","source":"Crossref","is-referenced-by-count":1,"title":["Are nucleot(s)ide analogues a negative factor for HBsAg seroconversion in acute hepatitis B?"],"prefix":"10.51821","volume":"87","author":[{"given":"MF","family":"Keser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2024,10]]},"reference":[{"key":"ref0","unstructured":"URIEL AJ, MARTIN P. Hepatitis Viruses. Encyclopedia of Microbiology. 1996(1):540-564."},{"key":"ref1","unstructured":"WORLD HEALTH ORGANIZATION GLOBAL HEPATITIS REPORT. viewed February 3, 2024. <https:\/\/iris.who.int\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf;jsessionid=DC3616B5BDF94FA8B6AC2FDBC71E5B51?sequence=1>"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"TOZUN N, OZDOGAN O, CAKALOGLU Y, IDILMAN R, KARASU Z, AKARCA U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-1026.","DOI":"10.1016\/j.cmi.2015.06.028"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"MCMAHON BJ, ALWARD WLM, HALL DB, HEYWARD WL, BENDER TR, FRANCIS DP, et al. Acute Hepatitis B Virus Infection: Relation of Age to the Clinical Expression of Disease and Subsequent Development of the Carrier State. J Infect Dis. 1985;151(4):599-603.","DOI":"10.1093\/infdis\/151.4.599"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"LOK AS, HEATHCOTE EJ, HOOFNAGLE JH. Management of hepatitis B: 2000\u2014Summary of a workshop. Gastroenterology. 2001;120(7):1828-1853.","DOI":"10.1053\/gast.2001.24839"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"KONDILI LA, OSMAN H, MUTIMER D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat. 2004;11(5):427-431.","DOI":"10.1111\/j.1365-2893.2004.00504.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"KUMAR M, SATAPATHY S, MONGA R, DAS K, HISSAR S, PANDE C, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45(1):97-101.","DOI":"10.1002\/hep.21486"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"TILLMANN HL, HADEM J, LEIFELD L, ZACHOU K, CANBAY A, EISENBACH C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13(4):256-263.","DOI":"10.1111\/j.1365-2893.2005.00695.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"JINDAL, A., KUMAR, M., SARIN, S. K. Management of acute hepatitis B and reactivation of hepatitis B. Liver international : official journal of the International Association for the Study of the Liver, 2013;33(1):164\u2013175.","DOI":"10.1111\/liv.12081"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"TERRAULT NA, LOK ASF, MCMAHON BJ, CHANG KM, HWANG JP, JONAS MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599.","DOI":"10.1002\/hep.29800"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"LAMPERTICO P, AGARWAL K, BERG T, BUTI M, JANSSEN HLA, PAPATHEODORIDIS G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"TOY M, OGUZ \u00d6NDER F, W\u00d6RMANN T, BOZDAYI AM, SCHALM SW, BORSBOOM GJ, et al. Age-and Region-Specific Hepatitis B Prevalence in Turkey Estimated Using Generalized Linear Mixed Models : A Systematic Review.; BMC Infectious Diseases 2011,(11):337","DOI":"10.1186\/1471-2334-11-337"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"AY P, TORUNOGLU MA, COM S, \u00c7IPIL Z, MOLLAHALILO\u01e6LU S, ERKO\u00c7 Y, et al. Trends of hepatitis B notification rates in Turkey, 1990 TO 2012. Eurosurveillance. 2013;(47):206-36.","DOI":"10.2807\/1560-7917.es2013.18.47.20636"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"PERRILLO RP, CHAU KH, OVERBY LR, DECKER RH. Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses. Gastroenterology. 1983;85(1):163-167.","DOI":"10.1016\/s0016-5085(83)80244-3"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"SHIFFMAN ML. Management of Acute Hepatitis B. Clin Liver Dis. 2010;(1):75-91","DOI":"10.1016\/j.cld.2009.11.013"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"SARIN SK, KUMAR M, LAU GK, ABBAS Z, CHAN HLY, CHEN CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;(1):1.","DOI":"10.1007\/s12072-015-9675-4"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"KEARNEY BP, FLAHERTY JF, SHAH J. Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics. Vol 43.; 2004.","DOI":"10.2165\/00003088-200443090-00003"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"LIU Y, CORSA AC, BUTI M, CATHCART AL, FLAHERTY JF, MILLER MD, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;(1):68-74.","DOI":"10.1111\/jvh.12613"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"ITO K, YOTSUYANAGI H, YATSUHASHI H, KARINO Y, TAKIKAWA Y, SAITO T, et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 2014;(1):89-97","DOI":"10.1002\/hep.26635"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"POND\u00c9 RA DE A. Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity. Arch Virol. 2019;(11):2645-2658.","DOI":"10.1007\/s00705-019-04369-9"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"STREINU-CERCEL A, SANDULESCU O, STEFAN M, Treatment with lamivudine and entecavir in severe acute hepatitis B. Indian J Med Microbiol. 2016;(2):166-172.","DOI":"10.4103\/0255-0857.176837"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"JOCHUM C, MAISCHACK F, ANASTASIOU O, VERHEYEN J, TIMM J, BECHMANN L, et al. Treatment of fulminant acute Hepatitis B with nucles(t)id analogues is safe and does not lead to secondary chronification of Hepatitis B. Z Gastroenterol. 2016;(12):1306-1311","DOI":"10.1055\/s-0042-120418"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T15:11:44Z","timestamp":1730301104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2181\/Are%20nucleot(s)ide%20analogues%20a%20negative%20factor%20for%20HBsAg%20seroconversion%20in%20acutehepatitis%20B\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.51821\/87.3.12462","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}